In HCC, glypican‐3 (GPC3), an oncofetal proteoglycan, is a TAA used as the CAR‐T‐cell therapy target in three completed clinical trials (NCT02395250, NCT02723942 and NCT03146234) and at least 11 ongoing studies.66 This evidence concerns the gene GPC3 and hepatocellular carcinoma.